U 67154
Latest Information Update: 28 Jul 1998
Price :
$50 *
At a glance
- Originator Pharmacia Corporation
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 28 Jul 1998 No-Development-Reported for Hyperlipidaemia in USA (Unknown route)
- 09 Mar 1995 Preclinical development for Hyperlipidaemia in USA (Unknown route)